[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335776-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335776-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dr6-augments-colorectal-cancer-cell-growth-invasion-and-stemness-original-article-activating-aktnf-b-pathway","DR6 Augments Colorectal Cancer Cell Growth, Invasion, and Stemness - Original Article - Activating AKT/NF-κB Pathway","","This study elucidates the role and mechanisms of Death Receptor 6 (DR6) in colorectal cancer malignant progression. DR6 expression and its association with patient survival were assessed using GEPIA CRC cohort data. DR6 function in CRC cells was tested with loss- and gain-of-function approaches, including CCK-8 proliferation, transwell migration and invasion, and sphere-forming assays, alongside a nude-mouse xenograft model to evaluate DR6 knockdown effects. Elevated DR6 predicted worse prognosis. Mechanistically, DR6 silencing reduced AKT and NF-κB phosphorylation, and an AKT activator (SC79) reversed the inhibitory effects, supporting DR6 as a clinical prognostic marker and therapeutic target via AKT/NF-κB signaling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dr6-augments-colorectal-cancer-cell-growth-invasion-and-stemness-original-article-activating-aktnf-b-pathway/335776/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dr6-augments-colorectal-cancer-cell-growth-invasion-and-stemness-original-article-activating-aktnf-b-pathway/335776.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this study on DR6 in colorectal cancer?","Question",{"text":63,"@type":64},"The study aims to clarify DR6’s role and underlying mechanisms in the malignant progression of colorectal cancer, focusing on how it influences cancer cell behaviors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers test DR6’s effects on colorectal cancer cells?",{"text":68,"@type":64},"They performed loss-of-function and gain-of-function experiments, using CCK-8 proliferation, transwell migration and invasion assays, and sphere-forming assays, and evaluated tumorigenesis with a nude-mouse xenograft model.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links DR6 to colorectal cancer progression?",{"text":72,"@type":64},"DR6 promotes malignancy by activating the AKT/NF-κB pathway. DR6 silencing lowered AKT and NF-κB phosphorylation, while the AKT activator SC79 counteracted these inhibitory effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335776,1790621018,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Biochemical Genetics (2025) 63:606–622  \n[https://doi.org/10.1007/s10528-024-10673-0](https://doi.org/10.1007/s10528-024-10673-0)  \nORIGINAL ARTICLE  \nDR6 Augments Colorectal Cancer Cell Growth, Invasion, and Stemness by Activating AKT/NF‑κB Pathway  \nJing Jia1 · Yisen Huang2 · Qiwei Chen1 · Jianbin Hou1 · Yan Liu1 · Lifeng Xie1 · Xinyu Li1 · Chunkang Yang3  \nReceived: 21 July 2023 / Accepted: 2 January 2024 / Published online: 13 March 2024 © The Author(s) 2024  \nAbstract  \nThis study aims to elucidate the role and mechanisms of Death Receptor 6 (DR6), a member of the tumor necrosis factor receptor superfamily, in the malignant progression of colorectal cancer (CRC) . The association of DR6 expression levels and CRC patient survival was examined using the CRC cohort data from GEPIA database. The functional role of DR6 in CRC cells was investigated by performing loss-of-function and gain-of-function experiments based on CCK-8 proliferation assay, transwell migration and invasion assay, and sphere-forming assays. Xenograft model of CRC cells in nude mouse was established to evaluate the impact of DR6 knockdown on CRC tumorigenesis. Elevated expression of DR6 was correlated with an unfavorable prognosis in CRC patients. In vitro functional assays demonstrated that silencing DR6 considerably suppressed the proliferation, migration, invasion, and stemness of CRC cells, whereas its overexpression showed an opposite effect. DR6 knockdown also attenuated tumor formation of CRC cells in the nude mice. Mechanistically, silencing DR6 reduced the phosphorylation of AKT and NF-κB in CRC cells, and the treatment with an AKT activator (SC79) abrogated the inhibitory effects of DR6 knockdown on the malignant features of CRC cells. Our data suggest that DR6 contributes to the malignant progression of CRC by activating AKT/ NF-κB pathway, indicating its clinical potential as a prognostic marker and therapeutic target for CRC.  \nKeywords Death receptor 6 · Colorectal cancer · Proliferation · Migration · Invasion · Stemness features  \nJing Jia, Yisen Huang and Qiwei Chen have equal contribution in this paper.  \nExtended author information available on the last page of the article  \nIntroduction  \nColorectal cancer (CRC) is the fourth most common malignancy and one of the leading causes of cancer-related deaths worldwide, with a gradually increasing incidence and high mortality rate (Wu et al. 2020 ; Li et al. 2021 ; Islam et al. 2022 ; Sun et al. 2021) . The 5-year and 10-year survival rates of CRC are 65% and 58%, respectively, which poses a serious threat for human health (Wu et al. 2020 ; Li et al. 2021 ; Islam et al. 2022 ; Sun et al. 2021) . Currently, surgical resection combined with chemotherapy and radiotherapy is the mainstream option for CRC treatment, which can significantly improve the survival of CRC patients (Wu et al. 2020 ; Li et al. 2021 ; Islam et al. 2022 ; Sun et al. 2021) . However, the prognosis in patients diagnosed with advanced CRC remains poor, and the postoperative cancer recurrence and metastasis are the leading causes of mortality (Ma et al. 2022 ; Yang et al. 2020) . With the rapid development and widespread application of second-generation sequencing technology, the molecular profiles of many cancers, including CRC, have been comprehensively characterized. This has enabled the application of molecular biomarkers as predictive and prognostic tools to assess the clinical outcome of CRC patients (Zhu et al. 2021 ; Martini et al. 2020) . Li et al. reported that the downregulation of MEIS1 expression in CRC was associated with a poor prognosis. MEIS1 functions as a tumor suppressor to inhibit CRC cell growth and tumor formation by suppressing DNA damage repair and increasing the sensitivity to oxaliplatin (Li et al. 2022) . Further, Long et al. conducted a review on the dysregulation of circular RNAs (circRNAs), their functions, and clinical significance in CRC progression (Long et al. 2021) . A growing body of evidence","cbCaivnhNzr4cALB","https://ap.wps.com/l/cbCaivnhNzr4cALB","pdf",1657731,17,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is the main purpose of this study on DR6 in colorectal cancer?\",\"answer\":\"The study aims to clarify DR6’s role and underlying mechanisms in the malignant progression of colorectal cancer, focusing on how it influences cancer cell behaviors.\"},{\"question\":\"How did the researchers test DR6’s effects on colorectal cancer cells?\",\"answer\":\"They performed loss-of-function and gain-of-function experiments, using CCK-8 proliferation, transwell migration and invasion assays, and sphere-forming assays, and evaluated tumorigenesis with a nude-mouse xenograft model.\"},{\"question\":\"What mechanism links DR6 to colorectal cancer progression?\",\"answer\":\"DR6 promotes malignancy by activating the AKT/NF-κB pathway. DR6 silencing lowered AKT and NF-κB phosphorylation, while the AKT activator SC79 counteracted these inhibitory effects.\"}]","DR6 Augments Colorectal Cancer Cell Growth, Invasion, and Stemness - Original Article - Activating AKT/NF-κB Pathway | PDF",1790012294,43]